ABT Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 12.68%. Abbott Laboratories's return on equity of 12.91% beat Boston Scientific Corp.'s return on equity of 12.55%.

Abbott Laboratories has a consensus price target of $133.39, signalling upside risk potential of 18.88%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Boston Scientific Corp. has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.14%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Boston Scientific Corp. quarterly revenues of $5.3B. Abbott Laboratories's net income of $1.8B is higher than Boston Scientific Corp.'s net income of $670M. Notably, Abbott Laboratories's price-to-earnings ratio is 30.19x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.43x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 27.89%. Abbott Laboratories's return on equity of 12.91% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Abbott Laboratories has a consensus price target of $133.39, signalling upside risk potential of 18.88%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.38%. Given that Intuitive Surgical, Inc. has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical, Inc. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.14%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Abbott Laboratories's net income of $1.8B is higher than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Abbott Laboratories's price-to-earnings ratio is 30.19x while Intuitive Surgical, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.43x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 12.96%. Abbott Laboratories's return on equity of 12.91% beat Insulet Corp.'s return on equity of 17.89%.

Abbott Laboratories has a consensus price target of $133.39, signalling upside risk potential of 18.88%. On the other hand Insulet Corp. has an analysts' consensus of $357.00 which suggests that it could grow by 47.59%. Given that Insulet Corp. has higher upside potential than Abbott Laboratories, analysts believe Insulet Corp. is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.412, suggesting its more volatile than the S&P 500 by 41.175%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.14%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than Insulet Corp. quarterly revenues of $783.8M. Abbott Laboratories's net income of $1.8B is higher than Insulet Corp.'s net income of $101.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 30.19x while Insulet Corp.'s PE ratio is 69.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.43x versus 6.39x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 15.71% compared to Abbott Laboratories's net margin of 27.59%. Abbott Laboratories's return on equity of 12.91% beat ResMed, Inc.'s return on equity of 25.44%.

Abbott Laboratories has a consensus price target of $133.39, signalling upside risk potential of 18.88%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 14.8%. Given that Abbott Laboratories has higher upside potential than ResMed, Inc., analysts believe Abbott Laboratories is more attractive than ResMed, Inc..

Abbott Laboratories has a beta of 0.749, which suggesting that the stock is 25.138% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.

Abbott Laboratories has a quarterly dividend of $0.63 per share corresponding to a yield of 2.14%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Abbott Laboratories pays 64.54% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11.5B, which are larger than ResMed, Inc. quarterly revenues of $1.4B. Abbott Laboratories's net income of $1.8B is higher than ResMed, Inc.'s net income of $392.6M. Notably, Abbott Laboratories's price-to-earnings ratio is 30.19x while ResMed, Inc.'s PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 4.43x versus 7.05x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.